ArticleBMC research notes2026
Celecoxib modulates inflammatory and immunoregulatory gene expression in human monocyte-derived dendritic cells.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) play a pivotal role in regulating immune responses, influencing both pro-inflammatory and anti-inflammatory environments. Given the critical role of the COX-2/PEG2 pathway in regulating DC maturation and cytokine production, we investigated whether selective COX-2 inhibition by celecoxib could shift human monocyte-derived dendritic cells (mDCs) toward a toerogenic profile. The impact of celecoxib treatment on the expression of various inflammatory and anti-inflammatory factors, including IL-12, TNF-α, IL-10, IDO, TGF-β, and STAT3, was evaluated. Our results demonstrate that the expression of key anti-inflammatory factors was enhanced in DCs, suggesting that COX-2 inhibition could promote a tolerogenic phenotype. In conclusion, the therapeutic modulation of DCs through COX-2 inhibition could have applications beyond autoimmune diseases, offering potential for broader immunomodulatory therapies. Further studies are required to validate these findings and explore clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.